Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,269 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT03260205
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
48
States / cities
Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

NCT00609622
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
sunitinib, mFOLFOX6, bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
81
States / cities
Fairhope, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653
View directory record Official record
Conditions
Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Apixaban, No systemic anticoagulant prophylaxis
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Not applicable Interventional

Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD

NCT03255057
View directory record Official record
Conditions
Acute Exacerbation of COPD
Interventions
Hemolung Respiratory Assist System, Invasive mechanical ventilation
Device
Lead sponsor
Alung Technologies
Industry
Eligibility
40 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Sacramento, California • Denver, Colorado • Newark, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

NCT00279201
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 79 Years
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
138
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 21, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

NCT03405792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, WHO Grade IV
Interventions
Temozolomide (TMZ), Optune System, Pembrolizumab
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neural Underpinnings of Turning

NCT05475236
View directory record Official record
Conditions
Aging
Interventions
Experimental: Locomotor Learning
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults

NCT01314911
View directory record Official record
Conditions
Influenza, Human
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
44
States / cities
Chandler, Arizona • Costa Mesa, California • Garden Grove, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting Phase 4 Interventional

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

NCT05180773
View directory record Official record
Conditions
Peripartum Cardiomyopathy, Postpartum
Interventions
Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo
Drug
Lead sponsor
Dennis M. McNamara, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
64
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Active, not recruiting Phase 3 Interventional

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

NCT03911505
View directory record Official record
Conditions
Pompe Disease (Late-onset)
Interventions
Cipaglucosidase Alfa, Miglustat
Biological · Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
0 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting Not applicable Interventional

The ROAMM-EHR Study

NCT06263322
View directory record Official record
Conditions
Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia
Interventions
Actionable remotely generated health data, Non-Actionable remotely generated health data
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
60 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting No phase listed Observational

National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

NCT02852031
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome (HLHS)
Interventions
Collaborative Learning Network
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 15 Months
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

NCT03417245
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, factor concentrates
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional Results available

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Esuberaprost, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

NCT03679975
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Riluzole Oral Soluble film (ROSF) 50 mg
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657
View directory record Official record
Conditions
Relapsed Refractory Multiple Myeloma
Interventions
AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib, Pomalidomide
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
48
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

NCT02460094
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy

NCT00233402
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexvix, Standard white light cystoscopy
Drug · Procedure
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
15
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional Results available

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

NCT01198002
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

NCT04578756
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
Interventions
Cariprazine Flexible Dose
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Dothan, Alabama • Bentonville, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

NCT03659929
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine Sulfate, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Encino, California • Garden Grove, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

NCT01922037
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
145
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 21, 2026, 2:42 AM EDT